Kitecrowd Kite Forum
Remember Me?
Kitecrowd Welcome to the Kitecrowd.
Private Sales Only: Sell on your kite gear here.
Or take a peak if you are looking for second hand kites, and other gear.
Forum Actions:
Forum Statistics:
Threads: 24,786 Posts: 162,904
Last Post:
Fixed Bridle:
You want it. Someone?s probably got it. This is the page to ask!
Forum Actions:
Forum Statistics:
Threads: 12,117 Posts: 57,113
Last Post:
Fixed Bridle:
Lost it? Had it stolen? Post here.
Forum Actions:
Forum Statistics:
Threads: 958 Posts: 3,872
Last Post:
What's Going On?
Kitecrowd Statistics
Threads 132,630 Posts 1,569,080 Members 26,865 Active Members 122
Welcome to our newest member,From Wikipedia, the free encyclopedia
Kite Pharma is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products with a primary focus on engineered autologous
therapy designed to restore the immune system's ability to recognize and eradicate tumors.
The , California-based company was founded in 2009 by , M.D., FACS, an Israeli-American oncologist, who served as the company's chairman, president and chief executive officer.
On August 28, 2017,
announced that it would acquire Kite Pharma for $11.9 billion in an all-cash deal, equating to $180 cash per share. The deal will add the promising
candidate to Gilead's existing portfolio. The acquisition was completed in October 2017. In October 2017, Kite Pharma’s therapy, Yescarta () became the first CAR-T therapy approved by the FDA for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.
ranked Kite Pharma 7th in its annual list of 50 Smartest Companies 2017.
(KTE-C19, ZUMA-3) is an investigational therapy (for the treatment of adult patients with relapsed or refractory
(ALL)) in which a patient's T cells are genetically modified to express a
designed to target the antigen , a protein expressed on the cell surface of B-cell lymphomas and leukemias. It has
(Dec 2015) for the treatment of patients with refractory
(PMBCL), and
In October, Kite Pharma entered into a Cooperative Research and Development Agreement with the
for the development and commercialization of products for the treatment of multiple cancer indications.
In December, the company announced data in its lead clinical development program with the NCI, demonstrating that Kite’s most advanced immunotherapy product candidate – KTE-C19 CAR – can produce robust and durable tumor shrinkage in patients with an aggressive form of non-Hodgkin’s lymphoma, known as
(DLBCL). The clinical data were presented at the 55th American Society of Hematology Annual Meeting.
In March, the company announced that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development granted
designation for the company's proposed therapy for DLBCL.
In June, Kite Pharma entered into an exclusive, worldwide license with the
to certain intellectual property related to -based product candidates that target the
for the treatment of cancers expressing NY-ESO-1.
In August, Kite Pharma announced findings from its ongoing clinical trial: 12 of 13 evaluable patients with advanced B-cell malignancies had complete remissions (8 patients) or partial remissions (4 patients) resulting in a 92% objective response rate. The results support Kite Pharma's plan to file an
(IND) application in the fourth quarter of 2014 to initiate a clinical trial of Kite Pharma's lead CAR-based product candidate, , in patients with DLBCL.
In January, Kite Pharma and
entered into a strategic research collaboration and license agreement to develop and commercialize the next generation of novel Chimeric Antigen Receptor (CAR) T cell immunotherapies based on Kite's engineered autologous cell therapy platform and Amgen's extensive array of cancer targets.
In May, Kite Pharma announced that the first patient in its Phase 1/2 clinical trial of KTE-C19 in patients with refractory aggressive Non-Hodgkin's Lymphoma has been treated.
In June, Kite Pharma and
announced they have entered into a collaboration agreement to co-develop and co-commercialize second generation T cell receptor product candidates directed against the human papillomavirus type 16 E6 oncoprotein incorporating gene editing and lentiviral technologies.
In July, Kite Pharma and the
announced that they have entered into a partnership to enhance the development of Kite's lead product candidate, KTE-C19, for the treatment of patients with refractory aggressive Non-Hodgkin's Lymphoma.
In September, Kite Pharma announced that it has expanded its collaboration with the . Kite and the NKI have entered into an agreement under which Kite will receive from the NKI the exclusive option to license multiple T cell receptor (TCR) gene sequences for the development and commercialization of cancer immunotherapy candidates targeting solid tumors. Kite has also expanded its access to additional resources and research facilities through a master services agreement with the NKI.
In October, Kite Pharma announced that it has entered into an exclusive, worldwide license with the National Institutes of Health (NIH) for intellectual property related to T cell receptor (TCR)-based product candidates directed against MAGE A3 and A3/A6 antigens for the treatment of tumors expressing MAGE, which include lung, pancreatic, gastric, and breast cancers, among others. In the same month, Kite Pharma announced that it has entered into a worldwide research and license agreement with Alpine Immune Sciences (AIS), a privately held biotechnology startup, to discover and develop protein-based immunotherapies targeting the immune synapse to treat cancer. AIS will grant Kite an exclusive license to two programs from its transmembrane immunomodulatory protein (TIP) technology, which Kite plans to further engineer into chimeric antigen receptor (CAR) and T cell receptor (TCR) product candidates. This collaboration will accelerate Kite's efforts to establish the next generation of engineered T cell therapies specifically designed to overcome the inhibitory mechanisms present in the tumor microenvironment.
In December, Kite Pharma announced that it has initiated a phase 1/2 clinical study of KTE-C19 (ZUMA-3) for the treatment of adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL). KTE-C19 is an investigational therapy in which a patient's T cells are genetically modified to express a chimeric antigen receptor designed to target the antigen CD19, a protein expressed on the cell surface of B-cell lymphomas and leukemias. In the same month, Kite Pharma and
announced they will partner to develop a next-generation, functionally integrated and automated manufacturing system for engineered T-cell therapy. Kite and GE Global Research—GE’s centralized R&D hub—said they aim to increase the availability of engineered T-cell therapies by speeding up development of automation technologies that have the potential to lower costs, operate faster, and minimize variability. Also in December, Kite announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation status to the Company's lead product candidate, KTE-C19, for the treatment of patients with refractory diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL), and transformed follicular lymphoma (TFL).
In January, it was announced that Kite Pharma has entered into a Cooperative Research and Development Agreement (CRADA) with the NCI for the research and clinical development of a fully human anti-CD19 chimeric antigen receptor (CAR) product candidate for the treatment of B-cell lymphomas and leukemias. Moreover, Kite Pharma announced that its European subsidiary has entered into a research and license agreement with
(LUMC) to identify and develop T cell receptor (TCR) product candidates targeting solid tumors that are associated with the human papillomavirus (HPV) type 16 infection.
In March, Kite Pharma has announced that it would be collaborating with , in order to evaluate the safety and efficacy of two of its novel therapies. The target population for the tests would be patients suffering from non-Hodgkin Lymphoma. The therapies in question, KTE-C19 and , would be tested in combination with each other.
In June, Kite Pharma and Cell Design Labs, Inc. announced a research collaboration and license agreement to develop next generation, precision-controlled chimeric antigen receptor (CAR) product candidates that incorporate Cell Design Labs’ molecular “on/off switch” technology. Also in June, Kite Pharma announced that it has entered into a new Cooperative Research and Development Agreement (CRADA) with the Experimental Transplantation and Immunology Branch (ETIB) of the National Cancer Institute (NCI) for the research and clinical development of T-cell receptor (TCR) product candidates directed against human papillomavirus (HPV)-16 E6 and E7 oncoproteins for the treatment of HPV-associated cancers.
In July, Kite Pharma announced that it has entered into an exclusive, worldwide license agreement with The Regents of the University of California, on behalf of the University of California, Los Angeles (UCLA), for technology to advance the development of off-the-shelf allogeneic T-cell therapies from renewable pluripotent stem cells.
In December, Kite Pharma and Vitruvian Networks, Inc., a pioneering cell and gene therapy software and analytics platform company co-founded by GE Ventures and the Mayo Clinic, announced a strategic partnership to create a software solution to support commercial availability of T-cell therapies. Together, the parties will design and develop a platform for patients, physicians and treatment centers that enables commercial-scale ordering, logistics, monitoring and delivery of autologous cell therapies if they are FDA-approved, including axicabtagene ciloleucel (formerly known as KTE-C19), Kite’s lead investigational engineered T-cell therapy for aggressive non-Hodgkin lymphoma.
In March, Kite announced results a clinical trial of
cells in around a hundred people with advanced .
In April, Kite has won the ‘Clinical Trial Result of the Year’ award for its CAR-T trial of Axicabtagene Ciloleucel in patients with Aggressive Non-Hodgkin Lymphoma at the 2017 Clinical and Research Excellence Awards. The award recognizes clinical achievements in the pharmaceutical industry and contribution to the advancement of therapies for unmet medical needs.
In August, Kite has filed the first CAR-T candidate in Europe, seeking approval of its
(KTE-C19) for two types of non-Hodgkin's lymphoma (NHL).
In March 2011, Kite Pharma received $15 million in
venture cash.
In May 2013, Kite Pharma completed a $35 million financing of Series A .
In April 2014, Kite Pharma completed a $50 million mezzanine private financing of convertible notes.
In May 2014, Kite Pharma filed a registration with the
(IPO) of its .
In June 2014, Kite Pharma sold 8,625,000 shares of its common stock in their IPO at $17.00 per share, for gross proceeds of $146.6 million. The company listed on the NASDAQ Global market under the symbol “KITE.”
In December 2014, Kite Pharma sold 4,007,750 shares of it common stock in their
at $54.00 per share, for gross proceeds of $216.4 million.
In March 2015, Kite Pharma acquired
(TCF), a privately held biotechnology company based in the Netherlands, for 20 million and renamed it – Kite Pharma EU. Per the deal, Kite Pharma has obtained license agreements with IBA GmbH, Sanquin Blood Supply Foundation and the
(NKI), which include the rights to select new intellectual property related to T-cell receptors (TCRs) developed at the NKI. Additionally, the TCF acquisition will allow Kite Pharma to access the European manufacturing facilities, paving way for the company to initiate development programs in the EU and build its presence in the region.
In December 2015, Kite Pharma sold 4,168,750 shares of its common stock in a
at $69.00 per share, for gross proceeds of $287.6 million.
In January 2017, Kite Pharma announced that it has partnered with
to develop and commercialize its cancer treatment therapy in Japan, putting the U.S. company in line to receive up to $250 million in payments, of the $250 million, Kite said it would receive $50 million as upfront payment. Also in January, Kite Pharma announced that it had formed a joint venture with
to develop and commercialize its cancer treatment in China. Kite Pharma said it would receive an upfront payment of $40 million from the joint venture, funded by Fosun Pharma as well as regulatory and commercial milestones totaling $35 million.
On August 28, 2017, Gilead Sciences announced that it would purchase Kite Pharma for $11.9 billion in cash ($180.00 per share).
On October 3, 2017 Gilead Sciences announced that it had completed the acquisition of Kite Pharma for 11.9 billion in cash ($180.00 per share).
. Kite Pharma. Retrieved 2 June 2016.
at the .. Kite Pharma. Retrieved 21 January 2015.
. fiercepharma.com. .
. investors.gilead.com.
. Gilead. 18 October 2017. Retrieved 24 December 2017.
. MIT Technology Review. 27 June 2017. Retrieved 22 February 2018.
. StreetInsider. 2 December 2015. Retrieved 2 December 2015.
. StreetInsider. 7 December 2015. Retrieved 7 December 2015.
. Kite Pharma . 16 October 2012. Retrieved 15 August 2014.
. Kite Pharma . 7 December 2013. Retrieved 15 August 2014.
. 7 December 2013. Retrieved 15 August 2014.
. Kite Pharma . 31 March 2014. Retrieved 19 May 2014.
.Kite Pharma. 6 June 2014. Retrieved 8 June 2014.
Ro, Sam (26 August 2014). . . Retrieved 27 August 2014.
. Reuters. 5 January 2015. Retrieved 21 January 2015.
. Kite Pharma. 5 January 2015. Retrieved 21 January 2015.
. MarketWatch. 21 May 2015. Retrieved 7 July 2015.
. NASDAQ. 22 June 2015. Retrieved 7 July 2015.
. StreetInsider.com. 1 July 2015. Retrieved 7 July 2015.
. Kite Pharma. 14 September 2015. Retrieved 20 October 2015.
. FiereceBiotech. 20 October 2015. Retrieved 20 October 2015.
. ThePharmaLetter. 28 October 2015. Retrieved 28 October 2015.
Demmitt, Jacob (28 October 2015). . GeekWire. Retrieved 28 October 2015.
. Genetic Engineering & Biotechnology News. 3 December 2015. Retrieved 7 December 2015.
. TheStreet.com. 7 January 2015. Retrieved 7 January 2015.
. FierceBiotech. 13 January 2016. Retrieved 13 January 2016.
Sandford, Miles (18 March 2016). . Journal Transcript. Retrieved 18 March 2016.
. StreetInsider.com. 2 June 2016. Retrieved 2 June 2016.
. BusinessWire. 20 June 2016. Retrieved 20 June 2016.
. BusinessWire. 25 July 2016. Retrieved 26 July 2016.
. StreetInsider.com. 13 December 2016. Retrieved 14 December 2016.
Whipple, Tom (). . The Times. (Subscription required (help)).
. Yahoo Finance. 6 April 2017. Retrieved 7 April 2017.
Taylor, Phil (1 August 2017). . PMLive. Retrieved 9 August 2017.
. Kite Pharma . 9 March 2011. Retrieved 29 July 2014.
. Kite Pharma . 15 May 2013. Retrieved 15 August 2014.
Orbach, Meir (18 May 2014).
(In Hebrew).
(Tel Aviv). Retrieved 19 May 2014.
McBride, Ryan (15 May 2013). . FierceBiotech. Retrieved 19 May 2014.
. Kite Pharma. 28 April 2014. Retrieved 19 May 2014.
Carroll, John (28 April 2014). . FierceBiotech. Retrieved 19 May 2014.
. Kite Pharma. 19 May 2014. Retrieved 19 May 2014.
. Kite Pharma. 20 June 2014. Retrieved 15 August 2014.
Calia, Michael (20 June 2014). . The Wall Street Journal. Retrieved 21 June 2014.
. Kite Pharma. 23 June 2014. Retrieved 15 August 2014.
. Reuters. 10 December 2014. Retrieved 10 December 2015.
. . 18 March 2015. Retrieved 18 March 2015.
Zacks.com (18 March 2015).. . Retrieved 18 March 2015.
. Reuters. 10 December 2015. Retrieved 10 December 2015.
Grover, Divya (9 January 2017). . Reuters. Retrieved 10 January 2017.
Mukhopadhyay, Akankshita (10 January 2017). . Reuters. Retrieved 10 January 2017.
. investors.gilead.com.
. investors.gilead.com.
: Hidden categories:英语作文—the. kite怎么写_百度知道
英语作文—the. kite怎么写
英语作文—the. kite怎么写
我有更好的答案
英语例文，仅供参考Kites have been around for thousands of years and they are a part of many different cultures around the world.In China,there's a long history to fly a kite in the Spring while usually the weather and wind are so suitable for this leisure and with the development of society,flying kite become to be a world wide sport.The most famous kite flying city in China is Weifang cit y in Shandong provience,every year there are numerous kite lovers go there to fly their own kites.希望对你有帮助
采纳率：70%
来自团队：
为您推荐：
其他类似问题
换一换
回答问题，赢新手礼包
个人、企业类
违法有害信息,请在下方选择后提交
色情、暴力
我们会通过消息、邮箱等方式尽快将举报结果通知您。you押韵的英语单词 完美作业网 www.wanmeila.com
关于英语单词的押韵 押韵的英文是rhyme. 有网上英语押韵词典。[][]参考资料：[]
有什么英语单词和star押韵 ban fan gain pain chain plain plan flan rain woman 暂时能想到的就这么多……
压韵的英语单词 pig:big bigwig brig dig earwig figgig hedgepig jig ludwig mig pigprig renege rig shindig sprig swigtrig twig whig wigkite:affright airtight alight alright aright axitebackbite backlight bight birthright bite blacklightblight bobwhite bombsight bright bullfight bytecalcite campsite checkbite chlorite cite cockfightmoon:attune baboon balloon bassoon bestrewn boonbuffoon cartoon cocoon commune coon croondoubloon dragoon dune festoon forenoon goonharpoon hewn immune impugn jejune junelagoon lampoon loon lune maroon mistuneflowerbiker bilker biller binder bircher biterbitter blabber blacker bladder blamer blanderblanker blazer bleacher bleaker bleater bleederblencher blender blighter blinder blinker blisterblither bloater blocker blonder bloomer bloopercheesechinese chippies cities civvies clergies cockneyscoffees coneys cookies coolies cooties copiescoulees counties countries coveys cowries coziescrannies crappies crazies crees crises croniescubbies curies curries curtseys curtsies daddies看这个网站[]，键入任意单词，显示与其押韵的所有单词，很不错的参考资料：[]
有什么英语单词和star押韵 guitar,far,bar
和play押韵的英文单词有哪些 dayawaysaybayclaylayray总之 -ay 作最後字母的字都可以
求谁有押韵的英语单词，好像是300个。例如air,hair,fair. 介绍一个免费的押韵词典.你打上你想要的字,就会出一大堆押韵词了.希望你喜欢.[]1.cake:ache, awake, backache, bake, beefcake, beefsteak, betake, brake, break, cake, cheesecake, clambake, cornflake, cupcake, daybreak, drake, earache, earthquake, fake, firebreak, flake, forsake, fruitcake, grubstake, hake, handshake, headache, heartache, heartbreak, hoecake, hotcake, housebreak, intake, jailbreak, jake, keepsake, lake, make, mandrake, mistake, muckrake, namesake, newsbreak, oatcake, offtake, opaque, outbreak, pancake, partake, quake, rake, remake, retake, sake, shake, sheik, sheikh, shortcake, slake, snake, snowflake, spake, stake, steak, strake, sweepstake, take, toothache, unmake, uptake, wake, windbreak2.some:adam, album, alum, angstrom, anthem, anum, ashram, atom, autumn, awesome, baalim, balsam, bantam, become, bedlam, belgium, benumb, blithesome, blossom, bonum, boredom, bosom, bottom, brougham, bum, buxom, centrum, chasm, chum, circum, column, come, condom, crumb, custom, czardom, darksome, datum, denim, dictum, diem, dorsum, drum, dukedom, dumb, dumdum, eardrum, earldom, edam, emblem, epsom, factum, fandom, fantom, fathom, fearsome, filmdom, flotsam, forum, foursome, freedom, fulcrum, gamesome, gingham, gladsome, gleesome, glum, graham, grandam, grewsome, gruesome, gum, gypsum, handsome, hansom, harem, harlem, ho-hum, hokum, hoodlum, hum, humdrum, income, irksome, ism, item, jetsam, kingdom, labrum, l......
请求一些押韵的英语单词，比如，girl和go.就像，爱和菜和盖和戴这些啊，要英语的，越多越好，谢谢了 [] 这里面有的是 看看吧 :-)
寻求与one押韵的英语单词 gun 枪支sun 太阳man 男人
求与high，lace，true。押韵的英语单词，最好6个以上。（一共18个） high, thigh, spy, shy, why, imply, nighlace, trace, base, pace, case, ace, facetrue, shoe, boo, tatoo, too, prove, school
有同一个韵脚的英语单词 中文的诗词，歌词要押韵。英语也是如此。英语的押韵或押韵词为rhyme。押韵词也叫做同韵词。英语同韵词的定义和种类。英语押韵的基本原则是：一个单词的元音和与这个元音相连的辅音与另一个单词的元音和与这个元音相连的辅音发音相同。如，cat 和hat,它们的元音a 和在a 后面的t 都发一样的音。两个同韵词至少要有一个不同的音。或是元音，或是辅音。在大多数情况下，是辅音。如果是两个发音完全相同但拼写不同的词，他们同音词，而不是同韵词。例如，wait 和weight，它们的发音都是w/a:/t. (长元音A). 这两个词是同音词，不是同韵词。英语同韵词有多种，包括尾韵词，结尾音节韵词，单韵词，双韵词，三韵词，前韵词，首音节韵词等等。下面来一一介绍。尾韵词End rhymes：两个单词结尾的元音加辅音相同。· Laughter, admirer· Blue, shoe· Hat, cat· Plate, eight· Marigold, button holed· Night, fight· Rain, pain· Fun, sun· Pay, say· Tin, pin结尾音节韵词last syllable rhymes：两个单词的最后一个音节的发音相同。· Tumor, harbor· Explain, plain,· Humanity, zesty· Threw, breakthrough· Pleat, complete双韵词double rhymes：两个单词的最后两个音节的发音相同。· Adoring, exploring,· Conviction, prediction· Walking, talking· Humming, coming· Navigator, waiter· Water, agitator· Singing, ringing· Friction, addiction三韵词triple rhymes：两个单词的最后三个音节的发音相同。· Frightening, brightening· Combination, explanation· Antelope, cantaloupe· Greenery, scenery· Mightily, vitally下面这两种韵词属于非常韵词，一般不归纳进韵词的范围。但是诗词，歌词作家们会运用这些韵词丰富自己的作品。前韵词beginning rhymes: 两个单词的最开始的辅音和元音的发音相同。· Physics, fizzle· Plantation, plan· Scenery, cedar· Cat, kangaroo· Table, tailor· Car, carpet· Soccer, sauce· Sole, soul· Game, gain首音节韵词first syllable rhymes: 两个单词的第一个音节的发音相同。· Carrot, caring· Pantaloons, pantomimes· Highlight, hydrant· Tulip, twosome· Extra, exhale· Explanation, excavate· Biangular, bite· Triple, trim· Fight, fire......